【Product for Licensing】Johnson & Johnson just licensed in a STAT6 inhibitor. If you are interested in similar assets, please contact us asap

If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap

On December 26, 2024, Johnson & Johnson (NYSE: JNJ) announced today that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.

Click here for more info.

If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap.

Many thanks!~

发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2024年12月27日 15:01
下一篇 2024年12月27日 16:58

相关推荐

公众号
公众号
分享本页
返回顶部